Cargando…

Erratum: The promise of neuroprotective agents in Parkinson's disease

Detalles Bibliográficos
Autores principales:	Seidl, Stacey E., Potashkin, Judith A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640195/ http://dx.doi.org/10.3389/fnins.2013.00069

Ejemplares similares

The Promise of Neuroprotective Agents in Parkinson’s Disease
por: Seidl, Stacey E., et al.
Publicado: (2011)

The emerging role of nutrition in Parkinson's disease
por: Seidl, Stacey E., et al.
Publicado: (2014)

Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease?
por: Valdés, Pamela, et al.
Publicado: (2016)

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
por: Santiago, Jose A., et al.
Publicado: (2017)

Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
por: Segura-Aguilar, Juan
Publicado: (2017)

Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson’ Disease
por: Santiago, Jose A., et al.
Publicado: (2017)

Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program
por: Santiago, Jose A., et al.
Publicado: (2018)

Melatonin: a promising neuroprotective agent for cerebral ischemia-reperfusion injury
por: Tozihi, Majid, et al.
Publicado: (2023)

The Impact of Disease Comorbidities in Alzheimer's Disease
por: Santiago, Jose A., et al.
Publicado: (2021)

Ginseng: a promising neuroprotective strategy in stroke
por: Rastogi, Vaibhav, et al.
Publicado: (2015)

Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine
por: Marashly, Eyad T., et al.
Publicado: (2017)

Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology
por: Santiago, Jose A., et al.
Publicado: (2017)

Transcriptomic and Network Analysis Highlight the Association of Diabetes at Different Stages of Alzheimer’s Disease
por: Santiago, Jose A., et al.
Publicado: (2019)

Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
por: Naqvi, Saba, et al.
Publicado: (2020)

Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
por: Hou, Lijuan, et al.
Publicado: (2017)

The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease
por: Błaszczyk, Janusz W.
Publicado: (2018)

Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
por: Gundersen, Vidar
Publicado: (2021)

Glutamic Acid Transporters: Targets for Neuroprotective Therapies in Parkinson’s Disease
por: Li, Xiang, et al.
Publicado: (2021)

Physical activity and lifestyle modifications in the treatment of neurodegenerative diseases
por: Santiago, Jose A., et al.
Publicado: (2023)

Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
por: Santiago, Jose A., et al.
Publicado: (2014)

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
por: Lindholm, Dan, et al.
Publicado: (2016)

Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes
por: Santiago, Jose A., et al.
Publicado: (2013)

Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
por: More, Sandeep Vasant, et al.
Publicado: (2015)

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease
por: Martinez, Bridget, et al.
Publicado: (2018)

Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease
por: Santiago, Jose A., et al.
Publicado: (2016)

Atrial Natriuretic Peptide Acts as a Neuroprotective Agent in in Vitro Models of Parkinson’s Disease via Up-regulation of the Wnt/β-Catenin Pathway
por: Colini Baldeschi, Arianna, et al.
Publicado: (2018)

Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients
por: Santiago, Jose A., et al.
Publicado: (2015)

Catalpol Exerts a Neuroprotective Effect in the MPTP Mouse Model of Parkinson’s Disease
por: Wang, Li-Yuan, et al.
Publicado: (2019)

Sex-specific transcriptional rewiring in the brain of Alzheimer’s disease patients
por: Santiago, Jose A., et al.
Publicado: (2022)

Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease
por: Stoessel, Daniel, et al.
Publicado: (2018)

Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson’s Disease
por: Liu, Mei-Fang, et al.
Publicado: (2018)

Fisetin Regulates Gut Microbiota and Exerts Neuroprotective Effect on Mouse Model of Parkinson’s Disease
por: Chen, Tian-Jiao, et al.
Publicado: (2020)

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
por: Reich, Niklas, et al.
Publicado: (2022)

Neuroprotective and therapeutic effects of calcitriol in rotenone-induced Parkinson’s disease rat model
por: Magdy, Alshimaa, et al.
Publicado: (2022)

Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism
por: Gómez-Soler, Maricel, et al.
Publicado: (2018)

Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment
por: Eker, Furkan, et al.
Publicado: (2023)

BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
por: Palasz, Ewelina, et al.
Publicado: (2020)

Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease
por: Esteves, Marta, et al.
Publicado: (2015)

Decreased soluble Nogo-B in serum as a promising biomarker for Parkinson's disease
por: Liang, Hongming, et al.
Publicado: (2022)

Oleanolic acid: a promising neuroprotective agent for cerebral ischemia
por: Caltana, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fij2tjf02nho1ah57ute6ouv8c